Form 4: Athira Pharma CMO's Routine Stock Sale for Tax

Athira Pharma's Chief Medical Officer, Javier San Martin, executed a mandatory 'sell to cover' transaction, disposing of 1,644 common shares at a weighted-average price of $6.88 following RSU vesting.

Summary

• Javier San Martin, Chief Medical Officer of Athira Pharma, Inc. (ATHA), reported transactions involving the company's common stock.
• On December 31, 2025, 4,667 shares of common stock were acquired due to the vesting of Restricted Stock Units (RSUs).
• The reported share numbers reflect an adjustment for the Issuer's 10-for-1 reverse stock split completed on September 17, 2025.
• Following this acquisition, Mr. San Martin beneficially owned 11,833 shares of common stock.
• On January 2, 2026, 1,644 shares of common stock were sold at a weighted-average price of $6.88 per share.
• The sale was a mandatory 'sell to cover' transaction to satisfy tax withholding and remittance obligations related to the RSU vesting, not a discretionary sale.
• The shares were sold in multiple transactions at prices ranging from $6.60 to $7.56.
• After the sale, Mr. San Martin beneficially owned 10,189 shares of common stock.
• Shares received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. in connection with a private placement in December 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing reports a mandatory 'sell to cover' transaction, which is a routine event for RSU vesting and not indicative of discretionary insider sentiment. The underlying RSU vesting is a positive for the executive, but the sale itself is neutral in terms of market signal.

Positives

• The vesting of 4,667 Restricted Stock Units (RSUs) indicates a component of executive compensation being realized.
• The reporting person's shares received from RSU settlement are subject to a lock-up agreement, which can signal commitment to the company's long-term prospects following a private placement.

Negatives

• The sale of 1,644 shares by a Chief Medical Officer, even if mandatory for tax purposes, reduces insider ownership.

Risks

• Market price fluctuations could impact the value of shares sold for tax obligations, potentially requiring more shares to be sold if the price drops.
• The lock-up agreement restricts the reporting person's ability to sell additional shares for a specified period, potentially limiting liquidity.

Future Outlook

This filing primarily reports past insider transactions and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details a routine insider transaction for an executive at a biotechnology company. Such 'sell to cover' transactions are common in the industry when restricted stock units vest, as executives need to cover tax liabilities. The mention of a reverse stock split and a private placement indicates recent corporate finance activities, which are typical for companies in the biotech sector seeking to manage share price and raise capital for research and development.

Corporate Governance

Related Party Transactions

• The transaction involves the sale of shares by a Chief Medical Officer, which is a form of executive compensation and a related party transaction.

Stakeholder Impact

• Shareholders: The mandatory 'sell to cover' transaction is a routine event and is unlikely to significantly impact shareholder sentiment, especially given the lock-up agreement on other shares. The reverse stock split and private placement mentioned are more significant events for shareholders.
• Employees (Executive): The vesting of RSUs represents a realization of compensation for the Chief Medical Officer.

Key Dates

Keywords

Athira Pharma, ATHA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Sale, Sell to Cover, Executive Compensation, Reverse Stock Split, Lock-up Agreement, Chief Medical Officer